Biopharmaceutical company ABVC BioPharma is set to receive $7 million in cash licensing income during 2025, stemming from global licensing agreements signed in 2023 for drug candidates targeting major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).
The projected revenue reflects milestone-based payments and underscores the company's strategic positioning in rapidly growing pharmaceutical markets. The global MDD market is expected to expand from $11.51 billion in 2022 to $14.96 billion by 2032, while the ADHD treatment market is projected to increase from $15.23 billion in 2022.
ABVC is simultaneously advancing its botanical drug development pipeline, with lead products progressing through clinical trials and demonstrating promising safety and efficacy profiles. The global botanical drug market, valued at $163 million in 2021, is forecasted to experience a robust 39% compound annual growth rate, potentially reaching $3.2 billion by 2030.
The company's strategic approach includes utilizing existing land assets to support research, development, and potential future partnerships. These initiatives align with ABVC's mission to deliver innovative therapeutic solutions addressing unmet medical needs through sustainable, plant-based innovations.
As a clinical-stage biopharmaceutical company, ABVC continues to leverage technology in-licensed from renowned research institutions, positioning itself for potential growth in competitive pharmaceutical markets.
